|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Progressive loss of striatal dopamine terminals in MPTP-induced acute parkinsonism in cynomolgus monkeys using vesicular monoamine transporter type 2 PET imaging([^(18)F]AV-133)显示文摘The 1-methyl-4-phenyl-1,2,3,4-tetrahydropyridine(MPTP)-induced parkinsonism model, particularly in non-human primates, remains the gold-standard for studying the pathogenesis and assessing novel therapies for Parkinson's disease. However, whether the loss of dopaminergic neurons in this model is progressive remains controversial, mostly due to the lack of objective in vivo assessment of changes in the integrity of these neurons. In the present study, parkinsonism was induced in cynomolgus monkeys by intravenous administration of MPTP(0.2 mg/kg) for 15 days; stable parkinsonism developed over 90 days, when the symptoms were stable. Noninvasive positron emission tomographic neuroimaging of vesicular monoamine transporter 2 with 9-[18F]fluoropropyl-(+)-dihydrotetrabenazine([18F]AV-133) was used before, and 15 and 90 days after the beginning of acute MPTP treatment. The imaging showed evident progressive loss of striatal uptake of [18F]AV-133. The dopaminergic denervation severity had a significant linear correlation with the clinical rating scores and the bradykinesia subscores. Thesefindings demonstrated that [18F]AV-133 PET imaging is a useful tool to noninvasively evaluate the evolution of monoaminergic terminal loss in a monkey model of MPTP-induced parkinsonism. | Yajing Liu Feng Yue Rongping Tang Guoxian Tao Xiaomei Pan Lin Zhu Hank F.Kung Piu Chan | 2014 | Neuroscience Bulletin2014，30，3： | 6 |
| 2 | Chinese expert consensus on conversion therapy for hepatocellular carcinoma(2021 edition)显示文摘Recent advances in systemic and locoregional treatments for patients with unresectable or advanced hepatocellular carcinoma(HCC)have resulted in improved response rates.This has provided an opportunity for selected patients with initially unresectable HCC to achieve adequate tumor downstaging to undergo surgical resection,a‘conversion therapy’strategy.However,conversion therapy is a new approach to the treatment of HCC and its practice and treatment protocols are still being developed.Review the evidence for conversion therapy in HCC and develop consensus statements to guide clinical practice.Evidence review:Many research centers in China have accumulated significant experience implementing HCC conversion therapy.Preliminary findings and data have shown that conversion therapy represents an important strategy to maximize the survival of selected patients with intermediate stage to advanced HCC;however,there are still many urgent clinical and scientific challenges for this therapeutic strategy and its related fields.In order to summarize and learn from past experience and review current challenges,the Chinese Expert Consensus on Conversion Therapy for Hepatocellular Carcinoma(2021 Edition)was developed based on a review of preliminary experience and clinical data from Chinese and non-Chinese studies in this field and combined with recommendations for clinical practice.Sixteen consensus statements on the implementation of conversion therapy for HCC were developed.The statements generated in this review are based on a review of clinical evidence and real clinical experience and will help guide future progress in conversion therapy for patients with HCC. | Hui-Chuan Sun Jian Zhou Zheng Wang Xiufeng Liu Qing Xie Weidong Jia Ming Zhao Xinyu Bi Gong Li Xueli Bai Yuan Ji Li Xu Xiao-Dong Zhu Dousheng Bai Yajin Chen Yongjun Chen Chaoliu Dai Rongping Guo Wenzhi Guo Chunyi Hao Tao Huang Zhiyong Huang Deyu Li Gang Li Tao Li Xiangcheng Li Guangming Li Xiao Liang Jingfeng Liu Fubao Liu Shichun Lu Zheng Lu Weifu Lv Yilei Mao Guoliang Shao Yinghong Shi Tianqiang Song Guang Tan Yunqiang Tang Kaishan Tao Chidan Wan Guangyi Wang Lu Wang Shunxiang Wang Tianfu Wen Baocai Xing Bangde Xiang Sheng Yan Dinghua Yang Guowen Yin Tao Yin Zhenyu Yin Zhengping Yu Bixiang Zhang Jialin Zhang Shuijun Zhang Ti Zhang Yamin Zhang Yubao Zhang Aibin Zhang Haitao Zhao Ledu Zhou Wu Zhang Zhenyu Zhu Shukui Qin Feng Shen Xiujun Cai Gaojun Teng Jianqiang Cai Minshan Chen Qiang Li Lianxin Liu Weilin Wang Tingbo Liang Jiahong Dong Xiaoping Chen Xuehao Wang Shusen Zheng Jia Fan 无 | 2022 | Hepatobiliary Surgery and Nutrition2022，11，2： | 4 |
| 3 | MPTP Induces Systemic Parkinsonism in Middle-Aged Cynomolgus Monkeys:Clinical Evolution and Outcomes显示文摘In this study,we developed a systemic PD model in middle-aged cynomolgus monkeys using individualized low-dose MPTP,to explore effective indicators for the early prediction of clinical outcomes.MPTP was not stopped until the animals showed typical PD motor symptoms on days 10 to 13 after MPTP administration when the Kurlan score reached 10;this abrogated the differences in individual susceptibility to MPTP.The clinical symptoms persisted,peaking on days 3 to 12 after MPTP withdrawal(rapid progress stage),and then the Kurlan score plateaued.A Kurlan score at the end of the rapid progress stage >15 reflected stable or slowly-progressive PD,while a score <15 indicated spontaneous recovery.The entire clinical evolution and outcome of the systemic PD model was characterized in this study,thus providing options for therapeutic and translational research. | Feng Yue Sien Zeng Rongping Tang Guoxian Tao Piu Chan | 2017 | Neuroscience Bulletin2017，33，1： | 3 |
| 4 | Study on Speeding up the Back-Propagation Algorithm显示文摘Slow convergence of back-propagation (BP) algorithm is a limiting factor in its practical applications. A new learning algorithm which can adaptively adjust its learning rate on the basis of gradient information of the error function is put forward. its convergence performance is also tested by the XOR problem compared with the standard BP algorithm. | TANG Ying SUN Rongping CHEN Kexing(Mechanical Engineering School, USTB, Beijing 100083, China) | 1997 | International Journal of Minerals,Metallurgy and Materials1997，11，4： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员